# Cancer Prevention Pharmaceuticals

Source: https://onco.cc/companies/cancer-prevention-pharmaceuticals/  
OnCo record `cancer-prevention-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer Prevention Pharmaceuticals is a Tucson company built around eflornithine, the polyamine-blocking drug, which it tested with sulindac in phase 3 to prevent polyps in familial adenomatous polyposis.

## Summary

Cancer Prevention Pharmaceuticals, founded in 2008 in Tucson, Arizona, develops eflornithine (DFMO), an ornithine decarboxylase inhibitor, for cancer prevention. Its phase 3 trials combined eflornithine with sulindac in familial adenomatous polyposis and in patients with a history of colorectal adenomas, registered on ClinicalTrials.gov under the company as lead sponsor; the combination did not reach approval, though eflornithine itself was later approved by another company for neuroblastoma maintenance.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Cancer Prevention Pharmaceuticals, Inc.; CPP
- Tags: ctgov-sponsor
- HQ: Tucson, AZ
- Type: biotech
- Website: https://canprevent.com

## Sources

- Official website: https://canprevent.com
- ClinicalTrials.gov: trials led by Cancer Prevention Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Cancer%20Prevention%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q50038303

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/cancer-prevention-pharmaceuticals.json